Time To Focus On GMP Activities Deferred By Pandemic, CDER Compliance Director Says
Executive Summary
US FDA’s Donald Ashley recaps the past year’s precedent-setting responses to the COVID-19 pandemic in Pink Sheet interview, while outlining a return to pre-COVID priorities and traditional inspection-based oversight.